These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

89 related items for PubMed ID: 29290199

  • 1. Lung Cancer with Concomitant Double Gene Mutation.
    Fan T, Liu XL, Zhou J, Song YJ, Yang H, Wei YN.
    J Coll Physicians Surg Pak; 2018 Jan; 28(1):72-73. PubMed ID: 29290199
    [Abstract] [Full Text] [Related]

  • 2. Advanced adenocarcinoma of the lung: comparison of CT characteristics of patients with anaplastic lymphoma kinase gene rearrangement and those with epidermal growth factor receptor mutation.
    Choi CM, Kim MY, Hwang HJ, Lee JB, Kim WS.
    Radiology; 2015 Apr; 275(1):272-9. PubMed ID: 25575117
    [Abstract] [Full Text] [Related]

  • 3. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
    Li W, Zhang Z, Guo L, Qiu T, Ling Y, Cao J, Guo H, Zhao H, Li L, Ying J.
    Oncotarget; 2016 Feb 16; 7(7):8332-40. PubMed ID: 26789109
    [Abstract] [Full Text] [Related]

  • 4. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
    Schmid S, Gautschi O, Rothschild S, Mark M, Froesch P, Klingbiel D, Reichegger H, Jochum W, Diebold J, Früh M.
    J Thorac Oncol; 2017 Apr 16; 12(4):681-688. PubMed ID: 28007627
    [Abstract] [Full Text] [Related]

  • 5. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
    Higuchi M, Owada Y, Inoue T, Watanabe Y, Yamaura T, Fukuhara M, Hasegawa T, Suzuki H.
    World J Surg Oncol; 2016 Sep 05; 14(1):238. PubMed ID: 27595749
    [Abstract] [Full Text] [Related]

  • 6. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
    Ulivi P, Chiadini E, Dazzi C, Dubini A, Costantini M, Medri L, Puccetti M, Capelli L, Calistri D, Verlicchi A, Gamboni A, Papi M, Mariotti M, De Luigi N, Scarpi E, Bravaccini S, Turolla GM, Amadori D, Crinò L, Delmonte A.
    Clin Lung Cancer; 2016 Sep 05; 17(5):384-390. PubMed ID: 26712101
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Lu S, Ye M, Ding L, Tan F, Fu J, Wu B.
    Oncotarget; 2017 Feb 07; 8(6):9996-10006. PubMed ID: 28036283
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
    Kim SJ, Kim DW, Kim TM, Lee SH, Heo DS, Bang YJ.
    J Clin Oncol; 2012 Jun 01; 30(16):e147-50. PubMed ID: 22508824
    [No Abstract] [Full Text] [Related]

  • 12. Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.
    Koizumi T, Fukushima T, Gomi D, Kobayashi T, Sekiguchi N, Mamiya K, Tateishi K, Katou A, Oguchi K.
    Med Oncol; 2017 Sep 01; 34(10):169. PubMed ID: 28864950
    [Abstract] [Full Text] [Related]

  • 13. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
    Park J, Kobayashi Y, Urayama KY, Yamaura H, Yatabe Y, Hida T.
    PLoS One; 2016 Sep 01; 11(8):e0161081. PubMed ID: 27518729
    [Abstract] [Full Text] [Related]

  • 14. [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
    Girard N.
    Bull Cancer; 2015 Jun 01; 102(6 Suppl 1):S96-9. PubMed ID: 26118885
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.
    Jpn J Clin Oncol; 2012 Jun 01; 42(6):528-33. PubMed ID: 22457323
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT.
    Choi H, Paeng JC, Kim DW, Lee JK, Park CM, Kang KW, Chung JK, Lee DS.
    Lung Cancer; 2013 Mar 01; 79(3):242-7. PubMed ID: 23261227
    [Abstract] [Full Text] [Related]

  • 19. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.
    Lee JO, Kim TM, Lee SH, Kim DW, Kim S, Jeon YK, Chung DH, Kim WH, Kim YT, Yang SC, Kim YW, Heo DS, Bang YJ.
    J Thorac Oncol; 2011 Sep 01; 6(9):1474-80. PubMed ID: 21642865
    [Abstract] [Full Text] [Related]

  • 20. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.
    Popat S, Vieira de Araújo A, Min T, Swansbury J, Dainton M, Wotherspoon A, Lim E, Nicholson AG, O'Brien ME.
    J Thorac Oncol; 2011 Nov 01; 6(11):1962-3. PubMed ID: 22005476
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.